Alerts will be sent to your verified email
Verify EmailDRREDDY
|
Dr. Reddy's Lab
|
Mankind Pharma
|
Zydus Lifesciences
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Number of ANDA's Filed in USA
|
367.0 . | 67.0 . | 481.0 . |
|
Number of ANDA's Approved By USFDA
|
294.0 . | 48.0 . | 419.0 . |
|
Domestic Sales Growth - YoY
|
9.1 % | 7.9 % | 6.7 % |
|
Global DMFs filed
|
1300.0 . | n/a | n/a |
|
R&D as a % of Total Sales
|
7.0 % | 2.2 % | 7.4 % |
|
Financials
|
|||
|
5 yr Average ROE
|
15.68 % | 20.33 % | 18.47 % |
|
5yr average Equity Multiplier
|
1.41 | 1.46 | 1.52 |
|
5yr Average Asset Turnover Ratio
|
0.74 | 0.81 | 0.66 |
|
5yr Avg Net Profit Margin
|
15.18 % | 17.68 % | 19.02 % |
|
Price to Book
|
2.77 | 6.92 | 4.12 |
|
P/E
|
17.3 | 52.38 | 21.58 |
|
5yr Avg Cash Conversion Cycle
|
74.48 Days | -13.08 Days | -84.89 Days |
|
Inventory Days
|
76.14 Days | 59.06 Days | 36.38 Days |
|
Days Receivable
|
95.44 Days | 34.35 Days | 36.93 Days |
|
Days Payable
|
102.6 Days | 121.69 Days | 160.15 Days |
|
5yr Average Interest Coverage Ratio
|
35.66 | 46.07 | 30.19 |
|
5yr Avg ROCE
|
21.82 % | 25.06 % | 19.65 % |
|
5yr Avg Operating Profit Margin
|
23.61 % | 24.62 % | 24.4 % |
|
5 yr average Debt to Equity
|
0.12 | 0.16 | 0.17 |
|
5yr CAGR Net Profit
|
23.71 % | 9.49 % | 16.23 % |
|
5yr Average Return on Assets
|
11.24 % | 14.46 % | 12.22 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
26.64 % | 72.67 % | 74.99 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-0.07 % | -3.83 % | 0.01 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.47 % | 5.95 % | -0.66 % |
|
Dr. Reddy's Lab
|
Mankind Pharma
|
Zydus Lifesciences
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
-
|
Operating Profit Break-Up
|
|
Therapeutic Area Break-Up
|
Therapeutic Area Break-Up
|
-
|
Therapeutic Area Break-Up
|
|
Asset Break-Up
|
Asset Break-Up
|
-
|
Asset Break-Up
|